Article: Suzuki Announces Pricing for 2010 Kizashi.

Article: CVT-3146 Increases Coronary Blood Flow Velocity in Phase ...
PR Newswire;  November 19, 2002 ;     700+ words ... ... 2002 CV Therapeutics announced today that CVT-3146 produced a dose-dependent increase ... CV Therapeutics is jointly developing CVT-3146, a selective A2A-adenosine receptor ... effect of a single rapid intravenous bolus of CVT-3146 on coronary blood flow velocity at ...

Article: Proving CVT technology
Automotive Industries;  February 1, 2003 ;     700+ words ...SUPPLY SIDE ZF CVT * ZF uses customer clinics, lab testing and a fleet of test vehicles to prove its CVT technology. When continuously variable transmission (CVT) technology was first introduced in the mid 1970s ...

Article: Is CVT the car transmission of the future? (continuously ...
Mechanical Engineering-CIME;  November 1, 1994 ;     700+ words ... ... improved design may make the belt-driven CVT the gear-change system of the future ... gasoline-fueled car with a rubber V-belt CVT. Since then, many attempts have been made ... British Torotrak toroidal traction-roller CVT system. Today, their geared counterparts ...

Article: Valuing Ranexa CVT Rejects $1B Acquisition Offer from ...
BIOWORLD Today;  January 28, 2009 ;     700+ words ... ... said Astellas had not received a response from CVT as of midday Tuesday. Tokyo-based Astellas ... for each share of Palo Alto, Calif.-based CVT. That represents a 41 percent premium to CVT's Monday closing price, which already was near ...

Article: Nissan driving CVT technology resurgence
Winnipeg Free Press;  August 11, 2006 ;     700+ words ... ... Netherlands car company, was the first to build a CVT in any volume. It used a simple rubber ... this trend, starting with their use of the CVT on the Murano SUV and now on the new 2007 ... sports-luxury sedan. They will add more CVT-equipped models in the near future until ...

Article: CV Therapeutics Announces CVT-3146 Phase I Clinical Data ...
PR Newswire;  May 8, 2001 ;     700+ words ... ... results from its Phase I clinical trial of CVT-3146 support initiation of Phase II clinical ... doses administered to healthy volunteers. CVT-3146 is a selective short acting coronary ... CV Therapeutics is jointly developing CVT-3146 with Fujisawa Healthcare, Inc ...

Article: CV Therapeutics Initiates CVT-3146 Phase I Clinical Trial ...
PR Newswire;  November 29, 2000 ;     700+ words ... ... have initiated a Phase I clinical trial for CVT-3146, a short acting selective A2A adenosine receptor agonist. CVT-3146 is being jointly developed for the ... blind, placebo-controlled trial of CVT-3146 in healthy volunteers. The goal ...